A painful, erythematous erosive enanthema, that interferes with feeding occurs at the onset of PV and precedes the appearance of skin lesions by 6 to 12 months. This painful, often non-specific stomatitis often delays diagnosis, especially when the patient presents to the dentist ( Figure 6 ). The delay in diagnosis is 5 months for the erosive-ulcerative form and longer, up to 8 months, for gingival involvement (31). This delay can be attributed to the clinician, the health care system or the patient (31, 32). It is even more important given the high frequency of oral involvement and the easy of oral access (32).

Mucosal lesions prevent feeding and used to be a cause of death. Painful enanthema may also occur in the oesophagus, conjunctiva, nasal mucosa or genital mucosa (vagina, vulva, penis, anal). Spread to the larynx causes hoarseness of speech. The bullous enanthema of immunological pemphigus is not associated with scarring due to its epidermal localisation as a result of achantolysis.

The gold standard for the diagnosis of enanthema, even retrospectively (33), is histopathological examination ( Figure 3 ) and direct immunofluorescence (DIF) IgG and/or C3 positivity (33) ( Figure 4 ), in addition to other serological tests, such as indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA). In the oral cavity, it is preferable to perform two biopsies, one from the tegument of the lesion and the other from the mucosal tissue (34), because the earlier pemphigus is diagnosed, the more effective the treatment (31, 32).

Pemphigus vegetans is characterised by a “cerebriform tongue”, which has been described since 1981 (35). The typical pattern of gyri and sulci over the dorsum of the tongue is a well-known sign of P. vegetans, as in the intertriginous involvement (35, 36). Intractable stomatitis with severe periorificial involvement facilitates the diagnosis of paraneoplastic Pemphigus (PNP) (37), whereas there is no mucosal involvement in PF (38).

The severity of mucosal lesions correlates with the distribution of Dsgl-3, which is present throughout the epidermis in the oral mucosa, in contrast to its cutaneous distribution (suprabasal, in the Malpighian layer) (13, 20, 39, 40). In pemphigus, the mucosal-dominant phenotype is associated with lymphocyte-predominant lesional inflammatory infiltrates of the skin (22). In PNP, we note the correlation of enanthema ( Figure 2 ) with the presence of both cadherins (Dsgl1, 3) and non-cadherin proteins (evoplakin, periplakin, bullous pemphigoid1,2 (BP1, 2)antigens, α-2-macroglobulin-like 1(A2ML1)) (13, 41).

The differential diagnosis of mucosal involvement in pemphigus is often difficult and includes other painful (aphthous ulcers, mucous membrane pemphigoid, herpetic stomatitis, polymorphous erythema of the moderate and severe forms) and painless enanthemas (lichen planus, florid oral papillomatosis, lupus erythematosus, oropharyngeal carcinoma).

Four types of pemphigus can cause intertriginous lesions: non-immune Hailey-Hailey pemphigus, immune vegetant pemphigus, PNP and the IgA form ( Figure 7 )

P. vegetans is initially bullous and rapidly develops vegetative lesions. Patients present with paronychia and nail dystrophy, often with nail haematomas (42). The presence of perivegetative pustules is seen in the moderate form of pemphigus vegetans and helps the clinician to differentiate this variant of Hallopeau’s pemphigus from the severe flaccid bullous Neumann’s disease (43, 44). In PNP, intertriginous lesions are not characteristic but may occur. The coexistence of enanthema, with periorificeal distribution and extensive lesions with a targetoid aspect, such as erythema multiforme, facilitates the clinical diagnosis (44, 45). IgA pemphigus presents with pruritic vesiculo-pustular lesions in the axillae, groin and proximal parts of the extremities (46).

Personal and family history is valuable in non-immunological Hailey-Hailey pemphigus, an autosomal dominant disease. Accurate diagnosis of intertriginous involvement is achieved by routine skin biopsy and DIF, supplemented by serological testing.

A classical clinical approach divides bullous diseases into pruritic, when there is a “subepidermal bulla”, and non-pruritic, when the bulla is located intra-epidermally. The term “subepidermal bulla” is inappropriate because the location of the vesicles/bullae is at the dermo-epidermal junction, part of the basement membrane.

Three forms of pemphigus may be associated with pruritus, sometimes of increased intensity: PF (61%) (47, 48), PH and IgA pemphigus. The parameter pruritus is related to the severity of the disease (48, 49) and indicates whether the disease is under control or not.

Research is needed in order to elucidate the role of T helper type 2-mediated pathways in comparing pruritus in pemphigus and bullous pemphigoid, BP (49). Other reports have shown a contribution of IL-31 (produced by the activated T-cell) and IL-31receptor α in PF and PH (49). IL-31 is a major pruritogen that has been widely described in atopic dermatitis, where it acts in the vicinity of nerve fibres and therefore has a nerve-targeting effect, which is not the case in pemphigus.

In PH, the mechanism by which IgG autoantibodies produce the characteristic skin lesions of PH (28, 50) is still debated, and the target antigens are usually Dsg1 and less commonly Dsg3. Non-Dsg cases may occur. According to Karray and coworkers (50), the intense inflammation may not be associated with acantholysis and PH has a broader epitope distribution compared to PV and PF. Proinflammatory cytokines released from activated keratinocytes include IL-8, which is involved in eosinophil and neutrophil chemotactic activity. Eosinophilia in the peripheral blood has been reported in some patients and may be associated with pruritus (28).

In IgA pemphigus, pruritus is an expression of IgA antibodies specifically directed against Dsgl-1, Dsgl3, Dsc-1. The precise immune cascade of IgA pemphigus remains elusive (28), but it is certain that PMNs infiltrate the integument, which is why the disease is often classified as a neutrophilic dermatosis.

Progress has been made in the diagnosis of this form of pemphigus with the introduction of diagnostic criteria for PH ( Figure 8 ) (51). The presence of pruritus, the herpetiform configuration of the lesions and the sparring of the mucosa are clinical features that need to be reinforced by the presence of IgG deposits in DIF.

Despite the name “herpetiform”, it has nothing to do with a viral infection. The same confusion may occur with dermatitis “herpetiformis” (Dühring-Brocq disease) or pemphigoid gravidorum (“herpes gestationis”).

The intense pruritus and vesiculo-bullous exanthema ( Figure 8 ) make clinical differentiation from a dermatitis herpetiformis or bullous pemphigoid difficult, but the presence of acantholysis and DIFpositivity (IgG) improves diagnostic accuracy. In other words, pemphigus herpetiformis may share clinical features with dermatitis herpetiformis and immunological features with immune pemphigus (51). Occasionally, autoantibodies are negative in pemphigus herpetiformis.

The variety of situations in which pemphigus herpetiformis migrates (both clinically and para-clinically) into either pemphigus foliaceus or pemphigus vulgaris is a diagnostic challenge that requires the expertise of the clinician (52–54).

Almost 6 decades after the initial description of photodistributed pemphigus erythematosus (PE) by Senear and Usher, Weston (1981) and Sontheimer (1979, 1982) described anti-Ro (SSA) and anti-La antibodies and their relationship to subacute lupus erythematosus. This type of Senear-Usher pemphigus is a superficial pemphigus ( Figure 9 ) that overlaps the features of lupus erythematosus, sometimes with these autoantibodies and/or dsDNA being positive. Some explanations correlate the coexistence of antiepithelial and antinuclear specificities (55) in PE.

In terms of clinical presentation, the bullous exanthema of PE affects the seborrhoeic areas and scalp, with “brain-like” lesions tending to crust (33, 56). Bullous systemic lupus erythematosus affects more women than men and the lesions are photodistributed (55, 56).

Histopathological examination provides elements of certainty according to the location of the bulla: subepidermal in bullous lupus (non-achantolytic) and intraepidermal (achantolytic) in Senear-Usher Pemphigus (44). DIF is also accurate and shows both the classic pemphigus focal deposits of IgG within the intercellular space (57) of the epidermis and the “lupic band” at the dermoepidermal junction (granular deposits of IgG and IgM) in Senear-Usher pemphigus. Based on the authors’ DIF experience, the epiluminescence microscopist may encounter this appearance on the same or different slides from the same patient. In patients with bullous lupus, linear or granular deposits (IgG, M, A, complement) along the dermo-epidermal junction are seen on DIF (56) due to autoantibodies directed against type VII collagen.

As a “neutrophilic dermatosis”, IgA pemphigus is a diagnostic challenge (58), and differentiation from Grover’s transient acantholytic dermatosis, Darier’s follicular dyskeratosis and Sweet’s neutrophilic dermatosis, is often difficult. Furthermore, even distinguishing between the two forms, subcorneal pustular dermatosis (SPD) and intraepidermal neutrophilic type (IEN type), requires an experienced team, dermatopathologist and dermatologist (58–60). The site of acantholysis in SPD is subcorneal, whereas in IEN it is inferior, i.e. suprabasal (44, 61).

The targets of IgA autoantibodies in SPD type are desmosomal cadherins (Dsc1, Dsc2, Dsc3), whereas no major autoantigenic profile has been identified in IEN type (62), suggesting that its autoantigenic profile is heterogeneous. Dsg are recognised by IgA antibodies in a few patients with IgA pemphigus (62). Intraepidermal proteolytic cleavage leading to acantholysis is mediated by PMNs, which accumulate with monocytes as a result of possible binding of IgA autoantibodies to the Fc receptor CD89.

Clinically, both forms of pemphigus IgA are associated with a pruritic, vesiculo-pustular exanthem (59) localised on the trunk and extremities, often confluent, with vesicles that rupture and crust centrally ( Figure 9 ). The intraepidermal neutrophilic variant has a characteristic configuration known as the “sunflower” (60, 61). In paediatric patients, the main differential diagnosis is the dermatosis with linear deposition of IgA. DIF resolves the problem with intraepidermal fluorescence in IgA pemphigus and linear basement membrane fluorescence in linear IgA dermatosis. Involvement of intertriginous areas raises differential diagnostic issues (see above).

We note the association of IgA pemphigus with monoclonal gammopathy (63), HIV infection (64), inflammatory bowel disease (65), rheumatoid arthritis (66), drug administration (immune checkpoint (67), inhibitors or thiol drugs) (68).

Recently, a new form of IgG/IgA pemphigus has been described, the clinicopathological features of which differ from those of classical IgG and IgA pemphigus (69, 70). IgG/IgA pemphigus is defined by the presence of IgG and IgA cell surface deposits on DIF and/or circulating IgG and IgA autoantibodies on IIF (70). The few case reports suggest that IgG/IgA pemphigus resembles IgG pemphigus in clinical features, IFD and IIF, but differs significantly from IgA patients in intertriginous distribution, pustular lesions, achantolysis and DIF (68, 69). Thus, Lehman and co-workers have suggested that IgG/IgA pemphigus may be a variant of IgG pemphigus rather than an IgA pemphigus (69, 70).

Another problem is the relationship between IgA superficial pemphigus (SPD) and Sneddon-Wilkinson subcorneal pustulosis, SWD, which is still considered a “spectrum of disease” (71).

Subcorneal pustular dermatosis, described by Ian Sneddon and Darrell Wilkinson in 1956, is a neutrophilic dermatosis and it is still unclear whether it is distinct from IgA pemphigus or is part of a spectrum of the same disease (72). IgA pemphigus was described 26 years later by Wallach, Foldes, and Cottenot as “subcorneal pustular dermatosis and monoclonal IgA”. IgA pemphigus is distinguished from SWD by a positive DIF ( Figure 4 ) showing intercellular IgA deposition (71, 73). Other authors define SWD as a “benign amicrobial pustulosis” that belongs to the spectrum of neutrophilic dermatoses and may be associated with IgA monoclonal gammopathy and other neutrophilic dermatoses (71).

In this rare form of pemphigus, there is no consensus on the mechanism of pathogenesis, but an interaction between genetic predisposition (HLA-DRB1) and environmental factors has been documented (74, 75). Acantholysis occurs as a result of two distinct processes: biochemical interactions at the basement membrane of keratinocytes (non-immune) and (intracellular) anti-Dsg1 and/or Dsg3 (immune) antibodies (76).

The offending chemical groups are thiol drugs (penicillamine, HLA-B15 predisposition), phenol group drugs (aspirin, rifampicin, anticonvulsant cephalosporins) and non-thiol/non-phenol drugs (converting enzyme inhibitors, checkpoint inhibitors) (75, 76).

Thiol drugs contain a sulfhydryl group (-SH) and are the most common drugs that induce pemphigus by biochemical modification of the antigen (74, 76). Three mechanisms have been correlated with achantholysis in thiol-containing drugs: neo-epitopes via interaction with Dsg1 and 3, alteration of the basal membrane via the keratinocyte (disulfide bond) and the pathway of proteolytic enzymes (plasmin) (75).

The phenolic group (-OH) acts at the level of the keratinocytes, which release TNF-α and IL-1, followed by activation of plasminogen and other proteases (74).

Non-thiol/non-phenolic drugs act through antibody formation. New immunological therapies such as checkpoint inhibitors are opening the door to cutaneous autoimmune diseases. Although checkpoint inhibitors are known to induce bullous pemphigoid (77), there are already reports that the combination of ipilimumab plus nivolumab can induce PV as an immune-related adverse event (3). It is important to note that pemphigus improves with drug withdrawal. Most reports of D-penicillamine-induced pemphigus vulgaris have been described in patients with rheumatoid arthritis (78). The question has been raised as to whether the treatment induces pemphigus or represents an association of the disease with rheumatoid arthritis, as pemphigus vulgaris has been described in patients with rheumatoid arthritis who are not taking penicillamine (78).

Pemphigoid (herpes) gestationis/gravidorum is an exclusive bullous dermatosis of pregnancy (79–81), but other immune bullous diseases may be found or worsen during pregnancy. It is not only difficult to treat but also to diagnose (81).

PV may worsen during pregnancy (81), especially in the first two trimesters, due to the Th2 predominance, in addition to the hormonal influence (oestrogen, progesterone, cortisol). In the third trimester, the chorion itself produces corticoids (endogenous) that can suppress autoimmune responses. The condition, which is fortunately rare, is associated with a risk of prematurity, infant death and pemphigus neonatorum, but the baby may be born healthy. Neonatal pemphigus may be due to transplacental transfer of IgG4 autoantibodies.

The term “syphilitic pemphigus” refers to congenital syphilis (82) (e.g. Treponema pallidum infection) and has nothing to do with “pemphigus”. The term derives from the fact that all bullous diseases were originally called “pemphigus”.

Described by Anhalt and coworkers in 1990 (83), PNP is associated with established or occult malignancies (37, 41, 84, 85), mainly haematological: non-Hodgkin’s lymphoma (86), chronic lymphocytic leukaemia (CLL) (87), Castleman’s disease ( Figures 4 , 7 ) (88), thymoma, and Waldenstrom’s macroglobulinemia (89). Clinically (41, 44, 45), the enanthema is severe, intractable (37, 41), with lesions around the mouth and nose. The exanthema also has erythema multiform-like lesions, which must be distinguished from other forms of pemphigus or even bullous pemphigoid. The authors have treated PNP cases in which the skin lesions were so extensive that the confluence of the plaques and the rupture of the bullae produced a TEN/Lyell-like appearance. In addition to skin lesions, damage to the respiratory epithelium can lead to death (90).

The term paraneoplastic autoimmune multi-organ syndrome (PAMS), classically described as PNP by Anhalt et al., indicates the severity of multisystem involvement (90).

Histopathological criteria include interface dermatitis and acantholysis throughout the epidermis (91). Ig G-type autoantibodies are directed against cadherin (Dsg1,3) but also against non-cadherin antigens (evoplakin, periplakin, BP1, 2 Ag and A2ML protein) (13, 85, 92). This explains why the appearance of DIF shows intercellular intraepidermal fluorescence, but sometimes an appearance suggestive of bullous pemphigoid (fine, linear and continuous basement membrane fluorescence in IgG autoantibodies). The diagnosis is supported by the new 2023 criteria (91, 92) ( Figure 10 ).

In eosinophilic spongiosis and pemphigus herpetiformis (52, 53), there is strong evidence for transition to other forms of pemphigus. Since 2002, cases of transition between PH and PF (52), PV vulgaris and PF (54, 93–95), naively or after treatment with rituximab (52, 53), have been reported. Transitions from PF to PV (53), PH to other forms, and eosinophilic spongiosis to PV or PF have also been documented. The topic is still controversial and the evidence for the rare cases so far is represented by anti-Dsgl ELISA autoantibodies.

The mechanism of the transition between PV and PF remains elusive (94) and the phenomenon of epitope spreading has been suggested. There are two types of immune response involved: a primary or inflammatory autoimmune response, which causes tissue damage by exposing the body’s immune system to a protein that evades immunological detection by the immune system, thereby triggering a secondary autoimmune response. Amino-terminal pathogenic antibodies to the EC domain of Dsg1 have been reported to be maintained during the transition from PV to PF, whereas significant epitope changes occurred in response to Dsg3, with an absolute or significant decrease in pathogenic antibodies to the EC1 domain of Dsg3 (95). The transition is associated with a decrease in anti-Dsg3 autoantibodies and an increase in Dsg1.

In terms of clinical presentation and prognostic value, autoantibody changes may be beneficial for a patient progressing from PV to the superficial forms. Some authors disagree with the shift between different forms of pemphigus, as recent reports of IgG/IgA pemphigus show heterogeneous clinical and histopathological presentations (68).

Genetically, there are two categories of pemphigus: familial genetic (Hailey-Hailey) and non-genetic, immunological ( Figure 11 ). The latter has an endemic form (Brazilian and Tunisian) and a non-endemic form.

The genetic form of acantholysis is non-immunological, the result of an autosomal dominant inheritance, and the chromosome involved is chromosome 3, with a mutation on its long arm (96). The ATP2C1 gene, which codes for the ATP-dependent Ca²⁺ and Mn²⁺ transporter, is mutated in such a way that the non-immunological acantholysis is related to Ca²⁺ at the Golgi apparatus of the keratinocytes.

Acantholysis is immunological in the non-genetic form as shown above. In the immunologically endemic Brazilian pemphigus (fogo selvagem), HLA class II DRB1*04, DRB1*16, DQB1*05 predominate (97) ( Figure 11 ). The endemic forms of pemphigus (Brazilian and North African, Tunisian) take into account the area of distribution of the disease, which has a multifactorial aetiology, in this case a familial predisposition. Salivary antigens from Simulium pruinosum (“black fly”) induce a cross-reaction leading to the production of autoantibodies against DSG1 in Brazilian pemphigus (20), where the disease occurs in members of the same family living near water. It is not clear why the incidence of the disease is lower in the northern regions where these insects are found, so other viruses or micro-organisms may be involved. Apoptosis is being studied, but other cell death has not been investigated, but mitochondrial autoantigens are acetylcholine receptors (20).

In immunologically non-endemic pemphigus there are associations with HLA Ag class II (DRB1*0402, DQB1*0302- in Jews) (98) and DQB1*0503, DRB1*0402 (Western Europe, North America and Brazil). There are numerous ethnic and geographical variations, not including endemic pemphigus, with high prevalence described in Ashkenazi Jews and Mediterranean populations (33). ST18 gene mutations confer a 6-fold increased risk of developing pemphigus vulgaris compared to the general population, via TNF-alpha, whose integumentary expression is increased (99, 100). A polymorphism of Dsg3 has been observed in association with pemphigus cls II susceptibility alleles, which may contribute to the development of PV (98). Although several attempts have been made to identify susceptibility traits, our knowledge of the genetic basis of PV is far from complete (99).

As shown above, an interaction between genetic predisposition (HLA-DRB1) and environmental factors has been documented in post-medication pemphigus.

More research is needed to understand the role of HLA molecules in immune pemphigus (98), mainly in the treatment, whereas amazing progress has been made in characterising them in psoriasis, where they correlate with different types of disease.

The place of DIF ( Figure 4 ) in the diagnostic staging of pemphigus forms is immediately after the histopathological examination in HE staining, which identifies the site of acantholysis and describes for each bulla: the ceiling, the floor and the contents (fluid in which the acantholytic cells float). “Spongiosis with eosinophils” is a histopathological feature characteristic of early pemphigus that the clinician should be aware of for two reasons: it is also seen at the onset of PB and, as mentioned above, it can be seen in other forms of pemphigus (28, 53).

DIF is an important diagnostic test (34, 101–103) in immunological pemphigus. The sensitivity of DIF is 94-98% (103, 104) with a positive predictive value of 90%, but a specificity of 36.3%. DIF is an accurate tool for confirming a definitive diagnosis (34, 102). Ideally, the dermatopathologist should note the concordance between routine HE and DIF.

The sampling technique is important: punch biopsies containing the bulla and perilesional tegument (3-10mm (34) are preferred on the skin, a formulation that also provides the necessary depth. This allows us to differentiate epidermal vesicles/bullae from deeper ones. In the mucosa, bleeding and local access complicate sampling. As mentioned above, ideally, two fragments should be obtained: the lesional tegument and the mucosal tissue (34).

If the site of acantholysis is important for histopathology, the DIF result will be positive or negative, indicating ( Figure 4 ): fluorescence of the stratum corneum (correct execution marker), intraepidermal immunoglobulin (Ig)G antibodies or C3 on the cell surfaces of keratinocytes (reticular intercellular IgG, IgA, C3). The site of acantholysis is not noted, only the fluorescent aspect. This pattern of deposition of IgG and C3 in intercellular space staining (ICS) has been termed “chicken wire” or “fish net” appearance. A positive DIF is one of the markers of PV relapse and is useful in monitoring the disease. In IgA pemphigus, fluorescence is superficial in SPD (restricted to the upper epidermal cell surfaces) and deeper in IEN (intercellular IgA deposition restricted to the lower epidermis or throughout the epidermis) (105–107). As mentioned above, these targets of IgA autoantibodies in SPD are desmosomal cadherins (Dsc1-3) (61).

The above mentioned DIF appearance in PNP is due to the attack initiated by both autoantibodies and CD8+ lymphocytes: intercellular and basement membrane deposition of IgG and C3, leading to confusion even with bullous pemphigoid. Interactions between neoplastic antigens and autoantibodies cross-reacting with epithelial antigens have been suggested. Another theory focuses on proinflammatory cytokines (IL-6) produced by autoantibodies synthesised by cancerous tumours. The presence of IgG and/or C3 in the ICS and in the basement membrane zone (BMZ) has been reported in less than 50% of cases. This is probably due to the expression of the bullous pemphigoid antigens BP1Ag and BP2Ag or the involvement of CD8+ lymphocytes in the initial attack (108).

In Senear-Usher erythematous pemphigus, a mixed pattern is seen on the slide or on different slides of the same specimen: a network in IgG and/or C3, as well as banded deposits at the dermal-epidermal junction, a “band-like” appearance, overlapping with pemphigus-erythematous lupus (58).

If DIF is negative on histopathological examination with acantholysis, the pemphigus is non-immunological (Hailey-Hailey or drug-induced non-immune form) or the case is treated with immunological remission. DIF may also be negative if the patient is receiving immunosuppressive treatment at the time of sampling (108), or if sampling and transport errors occur. If the DIF is false positive, a false reticulated appearance will be obtained due to technical deficiencies (freezing, crushing of the sample).

In situations where DIF is not available due to lack of epiluminescence microscope, staff training or reagents, the method could be replaced by IHC tests for IgG, C3d, C4 with efficient diagnostic reports. IHC on FFPE sections can be used as an alternative method to DIF (109). For example, a study of 20 patients with pemphigus vulgaris showed 85% positivity for IgG and 95% positivity for C3 on IHC, and 6 patients with pemphigus foliaceus showed 100% positivity for IgG and 75% positivity for C3 (109). Other authors have evaluated IHC for C4d in patients with immunological pemphigus and bullous pemphigoid. They found C4d deposits on intraepidermal DIF in 77.2% of patients, and the sensitivity of this technique was higher than that of classical serological techniques. This led to the suggestion that IHC could be considered in cases where serological tests were available (110).

These tests are minimally invasive, but their role is complementary and their value is indicative. They cannot replace the combination of histo-pathology and DIF (111), so their role is to increase diagnostic accuracy. Serological tests are mainly based on IIF and ELISA and detect circulating autoantibodies (112, 113).

IIF detects IgG and IgG4 autoantibodies (96, 113) on various substrates containing Dsg1 and Dsgl3. These substrates are monkey oesophagus (112), guinea pig oesophageal epithelium, normal human skin (incubated with NaCl to separate the epidermis from the dermis). The greater the number of substrates, the greater the accuracy of the method. The IIF substrate is basically a mosaic with 6 detection zones which can identify both autoantibodies against pemphigus and those directed against the BP1Ag and BP2Ag. Other types of substrate for IIF, such as primate liver tissue (useful for dermatitis herpetiformis), are not used for pemphigus. IIF antibody titre correlates with disease activity (112). A marker of PV relapse is positivity for antibodies to Dsg3.

The ELISA test is a sensitive diagnostic tool (112) that detects antibodies to Dsg 1, Dsg 3, -evoplakin, -collagen VII and BP-180, 230. It is useful for both screening and monitoring of pemphigus. In clinical practice, the multistep approach (112, 113) is recommended, with IIF screening followed by ELISA. The earlier this is done, the more reliable the diagnosis.

IgA pemphigus is serologically negative for Dsg1,3 and IgA positive for Dsc. In PH, serology is a diagnostic criterion with positive Dsg-1 antibodies (rarely Dsg3), Dsc 1,3 and an unknown 178kDa protein (16, 19).

Other serological tests include immunoblotting and immunoprecipitation, which detect rare autoantibodies (113, 114) (anti-laminin gamma 1, anti-laminin 332, anti-LAD-1, anti-alpha6, beta integrins, anti-Dsp, collagen VII). They are based on recombinant proteins or cell extracts and are used for screening rather than diagnosis. They require specialised laboratories and trained personnel and are laborious and time-consuming.

As shown above, PNP is associated with autoantibodies directed against cadherins, but also against periplakin, envoplakin, BP 1 and 2 antigens, and α2-macroglobulin-like-1 (A2ML1) protein. Drug-induced pemphigus involves Dsg 1 and 3, and IgA predominantly Dsg-1 (subcorneal pustulosis) or Dsg 1 and 3 in the deeper forms.

There are numerous case reports of individuals with positive antibodies to Dsg1 and Dsg3 antigens without a pemphigus phenotype. A 2018 study (115) found that almost half of subjects in a population in Amazonian Peru had positive anti-Dsg1 antibodies and approximately 25% had positive anti-Dsg3 antibodies in the absence of pemphigus lesions, highlighting the role of environmental and ethnographic factors.

Similarly, anti-Dsg antibodies have been reported in patients with inflammatory dermatological disorders: pyoderma gangrenosum, erythema multiforme major, atopic dermatitis, lichen planus pemphigoid, BP (116) or following viral infections or vaccination (117, 118).